Ketamine Use Disorder Classification
Ketamine use disorder is classified under "Other Hallucinogen Use Disorder" in DSM-5, specifically grouped with phencyclidine (PCP) and other hallucinogens. 1
DSM-5 Classification Framework
In DSM-5, ketamine falls within the broader category of hallucinogen-related disorders, where it shares diagnostic criteria with phencyclidine (PCP). This represents a shift from the previous DSM-IV structure, which separated substance abuse and dependence into two distinct diagnoses. 2
Key Changes in DSM-5
The DSM-5 Substance-Related Disorders Work Group made fundamental revisions that apply to ketamine use disorder:
- Combined abuse and dependence into a single "substance use disorder" diagnosis based on data from over 200,000 study participants 2
- Eliminated the hierarchical distinction between abuse and dependence that existed in DSM-IV
- Added craving as a diagnostic criterion while removing legal problems from the criteria set 2
- Introduced severity specifiers (mild, moderate, severe) based on the number of criteria met
Diagnostic Criteria Application
When diagnosing ketamine use disorder, clinicians apply the same 11-criterion framework used for other substance use disorders, requiring 2 or more criteria within a 12-month period for diagnosis. 1
Most Commonly Endorsed Criteria for Ketamine
Research demonstrates specific patterns in ketamine use disorder presentations:
- Continued use despite physical/psychological problems (59.0% endorsement rate) 1
- Withdrawal symptoms (30.2% endorsement) 1
- Physically hazardous use (29.8% endorsement) 1
The diagnostic criteria show moderate to excellent test-retest reliability (κ = 0.57-0.62) across different populations, confirming the validity of applying DSM-5 criteria to ketamine specifically. 1
Clinical Recognition Challenges
FDA-Recognized Abuse Potential
The FDA label explicitly acknowledges ketamine's abuse liability, noting that chronic ketamine use or abuse leads to specific complications including:
- Lower urinary tract symptoms (dysuria, frequency, urgency, incontinence, hematuria) 3
- Cystitis variants (interstitial, ulcerative, erosive, hemorrhagic) 3
- Biliary duct dilatation with recurrent use 3
- Persistent psychiatric adverse events lasting days to weeks after exposure 3
Important Caveat
The timeframe for ketamine withdrawal assessment may need reconsideration given that dissociative after-effects can persist for many hours, potentially confounding traditional withdrawal symptom evaluation. 1 This represents an area where the standard DSM-5 framework may require substance-specific adaptation for optimal clinical accuracy.